Literature DB >> 28089587

Development of 111In-labeled exendin(9-39) derivatives for single-photon emission computed tomography imaging of insulinoma.

Hiroyuki Kimura1, Hirokazu Matsuda2, Yu Ogawa3, Hiroyuki Fujimoto4, Kentaro Toyoda4, Naotaka Fujita4, Kenji Arimitsu5, Keita Hamamatsu4, Yusuke Yagi5, Masahiro Ono3, Nobuya Inagaki4, Hideo Saji6.   

Abstract

Insulinoma is a tumor derived from pancreatic β-cells, and the resulting hyperinsulinemia leads to characteristic hypoglycemia. Recent studies have reported the frequent overexpression of glucagon-like peptide-1 receptor (GLP-1R) in human insulinomas, suggesting that the binding of a radiolabeled compound to GLP-1R is useful for the imaging of such tumors. Exendin(9-39), a fragment peptide of exendin-3 and -4, binds GLP-1R with high affinity and acts as an antagonist. Accordingly, radiolabeled exendin(9-39) derivatives have also been investigated as insulinoma imaging probes that might be less likely to induce hypoglycemia. In this study, we synthesized a novel indium-111 (111In)-benzyl-diethylenetriaminepentaacetic acid (111In-BnDTPA)-conjugated exendin(9-39), 111In-BnDTPA-exendin(9-39), and evaluated its utility as a probe for the SPECT imaging of insulinoma. natIn-BnDTPA-exendin(9-39) exhibited a high affinity for GLP-1R (IC50=2.5nM), stability in plasma, and a specific activity that improved following reactions with a solvent and solubilizer. Regarding the in vivo biodistribution of 111In-BnDTPA-exendin(9-39) in INS-1 tumor-bearing mice, high uptake levels were observed in tumors (14.6%ID/g at 15min), with corresponding high tumor-to-blood (T/B), tumor-to-muscle (T/M), and tumor-to-pancreas (T/P) ratios (T/B=2.55, T/M=22.7, T/P=2.7 at 1h). The pre-administration of excess nonradioactive exendin(9-39) significantly reduced accumulation in both the tumor and pancreas (76% and 68% inhibition, respectively) at 1h after 111In-BnDTPA-exendin(9-39) injection, indicating that the GLP-1R mediated a majority of 111In-BnDTPA-exendin(9-39) uptake in the tumor and pancreas. Finally, 111In-BnDTPA-exendin(9-39) SPECT/CT studies in mice yielded clear images of tumors at 30min post-injection. These results suggest that 111In-BnDTPA-exendin(9-39) could be a useful SPECT molecular imaging probe for the detection and exact localization of insulinomas.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  (111)In; Exendin(9-39); Glucagon-like peptide 1 receptor; Insulinoma; Single-photon emission computed tomography

Mesh:

Substances:

Year:  2017        PMID: 28089587     DOI: 10.1016/j.bmc.2016.12.051

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  7 in total

Review 1.  Molecular imaging of β-cells: diabetes and beyond.

Authors:  Weijun Wei; Emily B Ehlerding; Xiaoli Lan; Quan-Yong Luo; Weibo Cai
Journal:  Adv Drug Deliv Rev       Date:  2018-07-03       Impact factor: 15.470

2.  Noninvasive longitudinal quantification of β-cell mass with [111In]-labeled exendin-4.

Authors:  Naotaka Fujita; Hiroyuki Fujimoto; Keita Hamamatsu; Takaaki Murakami; Hiroyuki Kimura; Kentaro Toyoda; Hideo Saji; Nobuya Inagaki
Journal:  FASEB J       Date:  2019-08-01       Impact factor: 5.191

3.  First-in-Human Evaluation of Positron Emission Tomography/Computed Tomography With [18F]FB(ePEG12)12-Exendin-4: A Phase 1 Clinical Study Targeting GLP-1 Receptor Expression Cells in Pancreas.

Authors:  Hiroyuki Fujimoto; Naotaka Fujita; Keita Hamamatsu; Takaaki Murakami; Yuji Nakamoto; Tsuneo Saga; Takayoshi Ishimori; Yoichi Shimizu; Hiroyuki Watanabe; Kohei Sano; Norio Harada; Hiroshi Nakamura; Kentaro Toyoda; Hiroyuki Kimura; Shunsaku Nakagawa; Mitsuharu Hirai; Atsushi Murakami; Masahiro Ono; Kaori Togashi; Hideo Saji; Nobuya Inagaki
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-19       Impact factor: 5.555

4.  Distinctive detection of insulinoma using [18F]FB(ePEG12)12-exendin-4 PET/CT.

Authors:  Takaaki Murakami; Hiroyuki Fujimoto; Keita Hamamatsu; Yuki Yamauchi; Yuzo Kodama; Naotaka Fujita; Junji Fujikura; Yoichi Shimizu; Yuji Nakamoto; Hiroyuki Kimura; Hideo Saji; Nobuya Inagaki
Journal:  Sci Rep       Date:  2021-07-22       Impact factor: 4.379

5.  Investigation of the preservation effect of canagliflozin on pancreatic beta cell mass using SPECT/CT imaging with 111In-labeled exendin-4.

Authors:  Keita Hamamatsu; Hiroyuki Fujimoto; Naotaka Fujita; Takaaki Murakami; Masaharu Shiotani; Kentaro Toyoda; Nobuya Inagaki
Journal:  Sci Rep       Date:  2019-12-04       Impact factor: 4.379

Review 6.  Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics.

Authors:  Irina Velikyan; Olof Eriksson
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

Review 7.  Non-invasive Beta-cell Imaging: Visualization, Quantification, and Beyond.

Authors:  Takaaki Murakami; Hiroyuki Fujimoto; Nobuya Inagaki
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-25       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.